RxDoctor Payments Data

Azam Shamani, MD

Family Medicine · San Diego, CANPI 1699906032

Payments from drug & device makers

$2,070in general payments, 2019–2025

Across 54 payments — averaging $38.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$486
  • GSK$417
  • Bayer$270
  • AbbVie$231
  • Boston Scientific$138
  • Cvrx, Inc.$122
  • plus $405 from 10 others

What the payments were for

  • Food & beverage$2,04099%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,070 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$229,524
Medicare patients
184
Services billed
3,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$103,393
JardianceEmpagliflozin49$54,286
MyrbetriqMirabegron47$40,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$38,130
EliquisApixaban38$32,095
ProliaDenosumab19$31,559
KerendiaFinerenone26$28,380
JanuviaSitagliptin Phosphate34$26,504
EntrestoSacubitril/Valsartan13$20,642
OxycontinOxycodone Hcl12$20,314
XareltoRivaroxaban20$20,064
LinzessLinaclotide11$14,745
PremproEstrogen,con/M-Progest Acet15$7,666
Spiriva HandihalerTiotropium Bromide14$7,332
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$5,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$103,39392 claims
Astellas Pharma US IncMyrbetriq$57$40,94047 claims
PfizerEliquis, Prempro$83$39,76253 claims
GSKTrelegy Ellipta$417$38,13058 claims
BayerKerendia$270$28,38026 claims
AbbVieLinzess$231$14,74511 claims
AstraZenecaSymbicort$486$3,95417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →